Combination strategies are currently being tested in different cancer types in an attempt to improve response rates [2,3], but the combination of cytotoxic lymphocyte antigen 4 (CTLA-4) blockade and programmed cell death receptor 1 (PD-1) blockade is well recognized to inevitably elicit higher toxicity and also implies a higher cost. Here, PDCD1 is linked to cancer.